190 related articles for article (PubMed ID: 26049698)
21. Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.
Laeseke PF; Chen R; Jeffrey RB; Brentnall TA; Willmann JK
Radiology; 2015 Dec; 277(3):644-61. PubMed ID: 26599925
[TBL] [Abstract][Full Text] [Related]
22. Stroma and pancreatic ductal adenocarcinoma: an interaction loop.
Luo G; Long J; Zhang B; Liu C; Xu J; Ni Q; Yu X
Biochim Biophys Acta; 2012 Aug; 1826(1):170-8. PubMed ID: 22521638
[TBL] [Abstract][Full Text] [Related]
23. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.
Nielsen MF; Mortensen MB; Detlefsen S
World J Gastroenterol; 2016 Mar; 22(9):2678-700. PubMed ID: 26973408
[TBL] [Abstract][Full Text] [Related]
24. Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography.
Raman SP; Horton KM; Fishman EK
Cancer J; 2012; 18(6):511-22. PubMed ID: 23187837
[TBL] [Abstract][Full Text] [Related]
25. Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications.
Chang J; Schomer D; Dragovich T
Biomed Res Int; 2015; 2015():269641. PubMed ID: 26146615
[TBL] [Abstract][Full Text] [Related]
26. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients.
Wong T; Howes N; Threadgold J; Smart HL; Lombard MG; Gilmore I; Sutton R; Greenhalf W; Ellis I; Neoptolemos JP
Pancreatology; 2001; 1(5):486-509. PubMed ID: 12120229
[TBL] [Abstract][Full Text] [Related]
27. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.
Wang XY; Yang F; Jin C; Fu DL
World J Gastroenterol; 2014 Nov; 20(42):15580-9. PubMed ID: 25400441
[TBL] [Abstract][Full Text] [Related]
28. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
29. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study.
Zubarik R; Gordon SR; Lidofsky SD; Anderson SR; Pipas JM; Badger G; Ganguly E; Vecchio J
Gastrointest Endosc; 2011 Jul; 74(1):87-95. PubMed ID: 21704809
[TBL] [Abstract][Full Text] [Related]
30. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis.
Iwanicki-Caron I; Basile P; Toure E; Antonietti M; Lecleire S; Di Fiore A; Oden-Gangloff A; Blanchard F; Lemoine F; Di Fiore F; Sabourin JC; Michel P
Am J Gastroenterol; 2013 Jan; 108(1):152-5. PubMed ID: 23287955
[No Abstract] [Full Text] [Related]
32. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
33. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
34. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
35. Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer.
Guo J; Xie K; Zheng S
Int J Biol Sci; 2016; 12(3):292-301. PubMed ID: 26929736
[TBL] [Abstract][Full Text] [Related]
36. Preoperative evaluation of pancreatic adenocarcinoma.
Parsons CM; Sutcliffe JL; Bold RJ
J Hepatobiliary Pancreat Surg; 2008; 15(4):429-35. PubMed ID: 18670846
[TBL] [Abstract][Full Text] [Related]
37. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer.
Liu F; Du F; Chen X
World J Surg Oncol; 2014 Nov; 12():333. PubMed ID: 25381564
[TBL] [Abstract][Full Text] [Related]
38. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
39. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer.
Al-Shaheri FN; Alhamdani MSS; Bauer AS; Giese N; Büchler MW; Hackert T; Hoheisel JD
Cancer Treat Rev; 2021 May; 96():102193. PubMed ID: 33865174
[TBL] [Abstract][Full Text] [Related]
40. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
Honda K; Kobayashi M; Okusaka T; Rinaudo JA; Huang Y; Marsh T; Sanada M; Sasajima Y; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Miura N; Kamita M; Sakamoto T; Shoji H; Jung G; Srivastava S; Yamada T
Sci Rep; 2015 Nov; 5():15921. PubMed ID: 26549697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
